ProfessorTom Marwick

Professorial Research Fellow

Menzies Institute for Medical Research

  • Professorial Research Fellow
    Menzies Institute for Medical Research
  • +61 3 85321550 (Work)
  • Menzies Institute for Medical Research, Menzies Institute for Medical Research, Hobart CBD Campuses, TAS

FUNDED PROJECTS

  • GRANT
    Cardio-Diabetic AI-guided Multi-disciplinary disease management program (CD-AIM)
    1 Jun 2026 - 31 May 2031
    People funded by this grant:
    • Marwick T,
    • Whitmore K,
    • Ridge A,
    • Radford J,
    • Wright L
    Project Total: $2,489,786; Could a screening protocol for subclinical LV dysfunction facilitate the selection of patients for a risk-based intervention, and thereby reduce incident HF? The goal of the Cardio-Diabetic AI-Informed disease Management program (CD-AIM) is to reduce the disability and morbidity that would otherwise arise from people with T2DM developing HF, and to preserve functional capacity and quality of life. The objectives are a) to screen asymptomatic individuals with T2DM and without established cardiovascular disease for SBHF with Artificial Intelligence (AI)-guided ECG and echocardiography, b) to undertake a multidisciplinary intervention with cardio-protective strategies, delivered by the study team (Research Nurses and Exercise Physiologists) to delay or prevent their progression to overt HF. Funded by: Medical Research Future Fund - Grant - Preventative and Public Health Research ($2,489,786); University of Tasmania.
  • GRANT
    PERCEIVE-Outreach: A scalable, risk-based model for managing persistent cardiovascular impact in Long Covid
    1 Jun 2026 - 31 May 2030
    People funded by this grant:
    • Huynh Q,
    • Marwick T,
    • Howden E,
    • Radford J,
    • Carrington M
    Project Total: $2,999,687; Despite starting as a respiratory infection by SARS-CoV-2, cardiac injury is commonly reported in COVID-19. Myocardial damage (inflammation and fibrosis), shortness of breath, and chronic fatigue are reported in most recovered patients after 2-3 months, and ongoing cardiac disability is likely a complication in Post-Acute Sequelae of COVID-19 (PASC, commonly known as Long COVID). This research aims to determine key factors that impact hospital admission and death in PASC. These findings will be used to develop a novel screening tool to identify those patients with a high risk of adverse outcomes and a world-first risk-guided healthcare program to effectively manage these risks in people with PASC. This research will include two study samples: A linked dataset provided by Department of Health includes all 7.5 million patients who tested either positive or negative with COVID-19 in Victoria during 2019-22. We will define PASC as monthly occurrence of direct healthcare costs for at least two out of three months after the initial COVID-19 infection to identify people with more severe PASC. This large dataset offers an opportunity to comprehensively investigate the burden of COVID-19. This will be complemented by our ongoing prospective cohort of 979 older Australians recruited from community, with 8-year follow-up (2015-23). This is the world-first paired data BEFORE and AFTER COVID-19 infection with excellent levels of data granularity to enable examination of most key factors of PASC prognosis. The development of a novel risk-guided healthcare program for PASC from our project will result in a reduction in adverse events, hospital admissions, costs, and improved quality of life. This will directly benefit not only millions of patients, but also our health system and clinicians and healthcare providers. It will maximise any investment return in the intervention, an outcome that will be particularly appreciated by healthcare providers with resource constraints. Funded by: Medical Research Future Fund - Grant - Emerging Priorities and Consumer Driven ($2,999,687); University of Tasmania.
  • GRANT
    Aortic Stenosis Screening Using aRtificial intelligence to acquire and interpret Echocardiograms (ASSURE-Echo)
    1 Aug 2025 - 31 Jul 2028
    People funded by this grant:
    • Marwick T,
    • Wright L,
    • Ouyang D,
    • Seidel B,
    • MacIntyre P
    Project Total: $304,920; Degenerative heart valve disease especially its most common serious manifestation, aortic stenosis will increase as the population ages. Recent work from our group has shown that unrecognised, clinically significant valve disease is present in 5% of the population. Because valve diseases are now treatable with minimally-invasive procedures, undiagnosed disease is a cause of preventable death and disability. Echocardiography is the cornerstone diagnostic test in cardiology, and the first step towards appropriate treatment of heart valve disease. Unfortunately, not everyone has the same access to echocardiography our previous work has documented differences in testing across different postcodes, even after correction for age. People living in Rural and Remote Australia (RRA) including but not restricted to the Aboriginal community have the lowest access. Limited access to diagnostic testing is an important contributor to late diagnosis of valve disease. This problem needs urgent remedy because it leads to unnecessary death and disability. Conventional echocardiography requires equipment, a sonographer, and an expert reader. Ultrasound equipment is now inexpensive and widely available, and this proposal will address the other requirements by using AI to both guide non-expert acquisition of echocardiography and provide recognition of aortic stenosis. Both acquisition and recognition components have been developed but this implementation science study will for the first time evaluate the feasibility of a community-based AI screening process for aortic stenosis. Lessons from this study will inform future strategies for the use of AI to improve access to echocardiography in rural and remote Australia. Funded by: Hospitals Contribution Fund Research Foundation - HCF - Hospitals Contribution Fund - Translational Research Grants ($304,926); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Cardio-Diabetic AI-guided Multi-disciplinary disease management program (CD-AIM)
    1 Jan 2025 - 31 Dec 2027
    People funded by this grant:
    • Marwick T,
    • Whitmore K
    Project Total: $350,000; The goal of the Cardio-Diabetic AI-Informed disease Management program (CD-AIM) seeks to reduce the disability and morbidity that would otherwise arise from progression of people with Type 2 Diabetes Mellitus (T2DM) to Heart Failure (HF), and preserve functional capacity and quality of life. The objectives are a) to screen asymptomatic individuals with T2DM and without established cardiovascular disease for Stage B Heart Failure (SBHF) with Artificial Intelligence (AI)-guided ECG and echocardiography, b) to undertake a multidisciplinary intervention with cardio-protective strategies, delivered by a national home-care provider (Amplar Health) to delay or prevent their progression to overt HF. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council; Baker Heart and Diabetes Institute; University of Tasmania.
  • GRANT
    Selection of Patients undergoing Transcatheter AVR for Rehabilitation
    1 Jan 2025 - 31 Dec 2025
    People funded by this grant:
    • Marwick T,
    • Morrison K,
    • Adams H,
    • Martin W
    Project Total: $24,964; This study seeks to improve mid to long term outcomes and reduce frailty in post-TAVR patients by implementing a 3-month CR program in an outpatient setting which will include individualised exercise and education. The proposed study aims to provide a model of care that can be implemented in future community settings. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,964); University of Tasmania.
  • GRANT
    Statins to reduce adverse cardiovascular effects from exposure to bushfire smoke
    1 Jan 2025 - 31 Dec 2028
    People funded by this grant:
    • Huynh Q,
    • Johnston F,
    • Marwick T,
    • Sharman J,
    • Carlsten C
    Project Total: $999,020; As severe bushfires increase around the world, more people are being exposed to longer and more extreme episodes of air pollution, which is the leading global environmental risk factor for cardiovascular diseases (CVD), such as heart attacks and stroke. Our research has two main goals: (1) to study how short-term (hours) and long-term (years) exposure to bushfire smoke affects early signs of cardiovascular disease, and (2) to test if statin medications reduce these negative effects over both the short and long term. Statin medications are commonly used to treat high blood cholesterol but have other useful actions such as anti-inflammatory effects. In theory, they have a lot of promise for protecting against many of the known harmful actions of air pollution on the cardiovascular system, but this has not been tested in practice. We will use existing data on air pollution and information from current studies and clinical trials to compare the effectiveness of statins compared with a placebo in the development and progression of CVD among people at low to medium risk. In Study 1 led by the Baker Institute, we will examine how long-term, exposure to general air pollution and bushfire smoke affects the buildup of plaque in the arteries. We will use cardiac CT scans to measure this plaque buildup and see if people taking statins had reduced impacts. We will also investigate whether the protective effects of statins varies among people with different levels of CVD risk. This will help plan the best individually tailored treatment strategies. In Study 2, led by Menzies, we will examine how short-term, exposure to bushfire smoke subtly affects heart, blood vessel and immune responses and find out if people using statins are protected against some of these effects. We will invite 50 participants from an existing long term study comparing statin treatment with a placebo, to join a trail involving controlled exposure to bushfire smoke for 2 hours and, at a separate time, to fresh filtered air for 2 hours. To avoids bias in the research, participants will not know if they are using a real statin or a placebo, and will not know the order of their exposure to the smoke or filtered air. The amount of smoke will set to levels commonly experienced in the community during burn-offs or on colder evenings in areas affected by wood-heater smoke. We are focusing on early, sub-clinical, signs of cardiovascular disease to: (1) safely study immediate changes and underlying mechanisms to learn more about how air pollution contributes to cardiovascular disease, and (2) to find potential problems and solutions at early stages of development of disease, well before air pollution leads to serious complications, such as a heart attack. The results of this research will guide treatments to lower overall risk and contribute to new strategies for protecting cardiovascular health during extreme smoke events. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Targeted Call for Research; Baker Heart and Diabetes Institute; Griffith University; La Trobe University; University of British Columbia; University of Sydney; Patient Experience Agency Ptd Ltd; University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Development of new technologies to improve diagnosis and risk evaluation of cardiac disease
    1 Jan 2024 - 31 Dec 2026
    People funded by this grant:
    • Marwick T
    Project Total: $102,000; Access to modern life-saving cardiology management hinges on appropriate diagnosis and risk evaluation. Unfortunately, modern diagnostic techniques are inaccessible to many patients, especially those living in rural and remote Australia. This project seeks to improve access to investigations by providing Artificial Intelligence-guided image acquisition and interpretation, new technologies available on point-of-care devices and recording of heart sounds for centralised and/or automated interpretation. Funded by: Baker Heart and Diabetes Institute ($102,000); University of Tasmania.
  • GRANT
    Reducing Cognitive impairment by management of Heart Failure as a Modifiable Risk Factor: Cog-HF
    Baker Heart and Diabetes Institute1 Jan 2024 - 31 Dec 2026
    People funded by this grant:
    • Marwick T,
    • Whitmore K
    Project Total: $340,483; Heart failure and dementia are common and serious problems in the community. Dementia and heart failure frequently co-exist due to shared disease processes and pathological mechanisms. Cognitive impairment – an important sign of dementia – is highly prevalent (>50%) in heart failure. The presence of one may lead to and/or worsen the other. This bidirectional relationship between dementia and heart failure acts as a vicious cycle that increases the burden of both diseases. We have successfully developed a disease management program for heart failure that are shown to reduce repeated hospital admission and mortality. These benefits appeared to be greater among patients with cognitive impairment who have higher risks of adverse outcomes. In this study, we aim to determine if these benefits among patients with cognitive impairment are due to an improvement in cognitive function. RCT to standard care versus an intensive disease management program that focuses on control of the body’s fluid volume, expedited treatment, self-care education and a novel exercise program delivered remotely via a smartphone or tablet application Funded by: Baker Heart and Diabetes Institute - Clinical Trial ($340,483); University of Tasmania.
  • GRANT
    SMART-Risk: A risk-guided strategy to reduce readmission for Acute Decompensated Heart Failure using mHealth
    1 Jan 2024 - 31 Dec 2025
    People funded by this grant:
    • Marwick T
    Project Total: $19,270; The aim of this study is to evaluate the impact of Smart-HF (a mHealth platform) on reducing readmission to hospital and other secondary outcomes. The Smart-HF platform is an app for the patient that delivers educational information, goal setting, homework tasks, self-monitoring, and questionnaires to patients with heart failure and allows patient progress and outcomes to be measured via a clinician portal. Participants are patients admitted to the general or cardiology wards with Acute Decompensated Heart Failure (ADHF). Enrolled patients classified with a high risk of hospital readmission and/or death - i.e., median of predicted risk, 33% based on the TAS-Help study algorithm developed by CIs Marwick and Huynh - will be randomised to either usual care or Smart-HF plus usual care, with stratification by study site and type of HF (reduced or preserved ejection fraction). The intensified home surveillance will show a reduction of hospital readmission and/or death (i.e., >50% risk) from use of Smart-HF. The primary endpoint is hospital readmission at 90 days post hospital discharge. Secondary endpoints - 30-day readmission, 30- and 90-day composite outcome. Funded by: Baker Heart and Diabetes Institute - Clinical Trial ($19,270); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Assessment of MEchaNical Dyssynchrony vs standard selection on clinical response in candidates for Cardiac Resynchronization Therapy (AMEND-CRT)
    1 Jan 2023 - 31 Dec 2027
    People funded by this grant:
    • Marwick T
    Project Total: $106,536; CRT (getting a pacemaker) is an effective treatment for many patients with heart failure and an abnormal echocardiogram (ECG), some people (a third or more) do not respond to this treatment (so the risk and discomfort of having a pacemaker inserted is without benefit), and a few people may actually get worse. The heart muscle normally contracts in a co-ordinated fashion so that all regions shorten at the same time. In some types of heart failure, this does not occur and different parts contract at different times, which is inefficient and can be corrected by a pacemaker. Some cardiac imaging methods can provide information about these mechanical disturbances (dyssynchrony?) in the heart that determine whether patients will and wont benefit from a pacemaker. In this research project we are trying to establish whether information from simple tests of the heart could be used to better select patients for CRT. If the tests do not identify the mechanical process that CRT corrects, we would then know that pacing would be ineffective, and a pacemaker implantation could be avoided. The aim of the study is to see whether people without abnormal mechanical function derive any benefit from CRT. We will assess this by follow-up ultrasound measurements, questionnaires and walking tests at 12 months. AMEND-CRT is a RCT with all participants receiving a CRT device (special pacemaker), as planned by their doctor. The insertion of the device will be done as it normally is during standard care. Of those people where the imaging test shows that benefit is unlikely, half will have the device turned on, and half will have the device left off for the duration of the study. Funded by: Baker Heart and Diabetes Institute ($113,720); University of Tasmania.
  • GRANT
    risk-guided Disease managEment plan to prevEnt CAD in patients with previous cancer (REDEEM-CAD)
    1 Jan 2023 - 31 Dec 2026
    People funded by this grant:
    • Marwick T
    Project Total: $394,875; Coronary artery disease (CAD) is a potentially serious illness. At the moment, there is no established strategy to screen cancer survivors for CAD. Traditional risk factors only allow us to identify some people at risk, and therefore we are missing some of those who need early treatment to prevent a heart attack/stroke and potentially unnecessarily treating others. The goal of the REDEEM-CAD study is to identify the feasibility and value of systematic risk evaluation and coronary calcium scoring as a component of survivorship care. Some new cardiac imaging methods have allowed the early detection of coronary artery disease before the patient develops symptoms or has a heart attack. In this project, we will undertake a CT cardiac scan to identify if there is coronary calcification. Prior to the cardiac CT a baseline health review will be undertaken. If there is calcification that meets protocol inclusion criteria, participants will be recommended appropriate therapy to stop progression of coronary disease usually involving statins, blood pressure control and lifestyle guidance regarding diet and exercise. This treatment will be under the guidance of the participants GP. Yearly visits at 12 and 24 months, final visit at 36months. Funded by: Baker Heart and Diabetes Institute - Clinical Trial ($394,875); University of Tasmania.
  • GRANT
    Assessing the clinical value of exercise stress echocardiography: an EXERcise stress Test collaboratION (EXERTION) study
    1 Jan 2022 - 31 Dec 2022
    People funded by this grant:
    • Schultz M,
    • Sharman J,
    • Roberts-Thomson P,
    • Marwick T,
    • Otahal P
    Project Total: $24,951; The primary objective of this study is to determine the clinical value of ESE in the prediction of CAD compared to an exercise stress ECG test. Specifically, we aim to determine the association of ESE test result with 1) probability of subsequent coronary angiogram procedure, and 2) the risk of CAD (as confirmed by coronary angiography) in comparison to that of an age- and sex-matched group of participants who completed a simple exercise stress ECG test. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,951); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Persistent cardiovascular effects of COVID-19 viral infection trial (PERCEIVE-RCT substudy): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
    1 Jan 2022 - 31 Dec 2025
    People funded by this grant:
    • Marwick T,
    • Whitmore K,
    • Schultz M
    Project Total: $533,322; There is some evidence that COVID-19 infection may lead to a risk of heart muscle damage. If this process is left unchecked, it might lead to heart failure, especially as individuals grow older and develop other risks for heart failure. Some cardiac imaging methods have allowed the early detection of cardiac problems before the patient develops heart failure. The study is aimed to identify cardiac complications of COVID-19 and find exercise and medical treatments that will improve these complications. Funded by: Baker Heart and Diabetes Institute ($533,324); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Risk-guided Disease managEment plan to prevEnt heart failure in patients treated with previous cheMotherapy (REDEEM)
    1 Jan 2022 - 31 Dec 2025
    People funded by this grant:
    • Marwick T,
    • Sharman J,
    • Whitmore K,
    • Schultz M
    Project Total: $339,163; The study aims to identify cardiac complications of cancer treatment (chemotherapy) and find exercise and medical treatment that will improve these complications. Some cancer treatments lead to a risk of heart muscle damage. If this process is left unchecked, it can sometimes cause heart failure, especially as patients grow older and develop other risks for heart failure. In this project an ultrasound of the heart (echocardiogram) will be taken in order to measure cardiac status. We are trying to establish whether information from simple tests of the heart could guide treatment to protect patients from developing heart failure. Funded by: Baker Heart and Diabetes Institute ($339,163); University of Tasmania.
  • GRANT
    Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring (EDCAD-PMS)
    1 Jan 2021 - 31 Dec 2023
    People funded by this grant:
    • Marwick T,
    • Whitmore K,
    • Sharman J
    Project Total: $149,300; The research will assess whether genetic (polygenic?) risk scores can improve patient selection for more advanced screening tests, such as coronary imaging or angiograms?, and risk factor management such as elevated cholesterol Main aims for this study are to identify whether: * Polygenetic risk score (PRS) and metabolic risk score can predict the presence of coronary calcium * Knowledge of the PRS result is better or worse than knowledge of the CT scan result in guiding people to reduce their risk (by changing lifestyle and taking medications) Funded by: Baker Heart and Diabetes Institute - Clinical Trial ($149,300); University of Tasmania.
  • GRANT
    Risk-guided strategy for reducing readmission for Acute Decompensated Heart Failure (RiskHELP)
    1 Nov 2019 - 30 Jun 2022
    People funded by this grant:
    • Marwick T,
    • Sharman J,
    • Whitmore K,
    • Dwyer N,
    • Izzettin O
    Project Total: $107,400; A prospective RCT with 320 HF randomised patients admitted with Acute Decompensated Heart Failure (ADHF) confirmed by diagnosis from RHH. Eligible patients (based on study inclusion exclusion criteria), identified by applying the TAS-Help (Study based at Menzies) algorithm as being at high risk for hospital readmission and/or death, will be randomised into two groups of 160 patients each arm. The control arm will receive usual care while the intervention arm will receive DMP-Plus. Patients with ADHF will be screened for a period of 24 months or until targeted sample size is met. Funded by: Medical Research Future Fund - Grant - Keeping Australians Out of Hospital; Baker Heart and Diabetes Institute; University of Tasmania.
  • GRANT
    Effectiveness of imaging pathways for CVD epidemics of the elderly
    1 Dec 2017 - 30 Nov 2021
    People funded by this grant:
    • Marwick T,
    • Chew D,
    • Kaye D,
    • Negishi K,
    • Stocks N
    Project Total: $703,875; Cardiovascular imaging, especially echocardiography, is a cornerstone of modern cardiology; guidelines stipulate the use of echocardiography to inform therapeutic intervention in heart failure and valvular heart disease. However, there is also a risk of overuse, and in contrast to North America, where the growth of imaging has been controlled over the last decade, use in Australia continues to grow at ~10% per year. The dependence on imaging is greater in the cardiovascular disease (CVD) epidemics of the elderly (atrial fibrillation [AF], aortic stenosis [AS] and heart failure [HF]) than in other diagnoses. Not only are large numbers of tests being done currently, but the growth of these conditions will magnify the problem over the coming years. Failure to manage the hospitalisation, device and procedural costs for treatment of these new CV epidemics can be linked to shortcomings in the practice of CV imaging. The need for ongoing surveillance that is heavily dependent on cardiac imaging will introduce new complexities around imaging quality. Despite the expenditure of ~$1 billion/year on CV imaging in Australia, there is little evidence of value. The Partnership will link researchers with providers and imaging industry to improve all steps of the imaging 'value chain' - ranging from the selection of suitable patients to the quality of interpretation. These studies will improve appropriate selection for testing, quality control and integration of decision-making with imaging. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Partnership Project; University of Tasmania.
  • GRANT
    Cardiometabolic risk trajectories from childhood to midlife: finding pathways to better health
    1 Jan 2017 - 31 Dec 2020
    People funded by this grant:
    • Venn A,
    • Marwick T,
    • Blizzard L,
    • Magnussen C,
    • Gall S
    Project Total: $1,531,986; Using data from a large cohort of Australian children followed for over 30 years, this study will investigate how weight status and physical fitness from childhood to adulthood determine early markers of cardiovascular disease and type 2 diabetes (cardiometabolic disease) in midlife. It will provide much needed evidence to address the high prevalence of cardiometabolic disease risk factors in young Australians through better targeted disease prevention and early clinical intervention strategies. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Project ($3,063,972); University of Tasmania.
  • GRANT
    Improved cardiovascular Disease hEALth service delivery in Australia (the IDEAL study)
    1 May 2016 - 1 May 2019
    People funded by this grant:
    • Sharman J,
    • Schultz M,
    • Marwick T,
    • Thomson P
    Project Total: $429,678; This program will establish and test the clinical value of a health service method to deliver patient information on cardiovascular disease (CVD) risk to general practitioners. This new method to measure and report absolute CVD risk will be developed within Tasmanian Pathology Services and tested by clinical-trial with linkage to CVD outcomes. Funded by: Royal Hobart Hospital Research Foundation - Grant - Project Grant Funding ($429,678); University of Tasmania.
  • GRANT
    Linking exercise blood pressure to clinical outcomes: the EXERcise stress Test collaboratION (EXERTION) Tasmanian pilot study.
    1 Jan 2016 - 30 Jun 2017
    People funded by this grant:
    • Schultz M,
    • Sharman J,
    • Venn A,
    • Marwick T,
    • Thomson P
    Project Total: $10,000; The EXERcise stress Test collaboratION (EXERTION) aims to link clinical exercise testing results to cardiovascular disease outcomes, to provide the first-ever evidence-based thresholds for abnormal exercise blood pressure. Results will inform clinical guidelines, providing supervising clinicians with signposts of cardiovascular risk upon which to optimise patient management and follow-up care. Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($10,000); University of Tasmania.
  • GRANT
    The EXERcise stress Test collaboratION - Pilot study
    1 Jan 2016 - 31 Dec 2017
    People funded by this grant:
    • Schultz M,
    • Sharman J,
    • Marwick T,
    • Venn A
    Project Total: $55,519; Data-linkage study investigating CV outcomes in relation to exercise stress testing, derivation of exercise BP thresholds. Funded by: Heart Foundation - Grant-Vanguard ($55,519); University of Tasmania.
  • GRANT
    Use of Advanced Cardiac Imaging in Radiation-Related Cardiotoxicity.
    1 Apr 2015 - 30 Jun 2016
    People funded by this grant:
    • Marwick T,
    • Nolan M,
    • Negishi K
    Project Total: $90,000; Successful advances in oncology over past decades have led to 5-year cancer survival rate improving from 50% in 1975-77 to 68% in 1999-2005. This success has led to a large pool of cancer survivors who are at substantial risk of cardiovascular morbiity and mortality. The specific complication of chemotherapy-induced cardiotoxicity (CTX), including radiotherapy cardiotoxicity, may occur in up to 20% patients within 5 years, and has a 50% mortality rate by 2 years. Cardioprotective (CP) medications have been demonstrated to reduce the risk of CTX, but uniform use would impose a financial burden on the health care system and expose many patients to unnecessary side-effects. One means of targeting CP to patients most likely to benefit is the use of novel echocardiographic techniques to detect preclinical cardiac damage. 2D-strain echocardiography measures changes in regional myocardial deformation, and identifies an earlier stage of cardiac dysfunction than the current standard of using left-ventricular-ejection-fraction (LVEF)-guided therapy. By identifying patients at an earlier stage,it is likely possible to target patients during a window when they are more likely to be responsive to CP, and avoids uneccessarily exposing patients who would never develop CTX to side-effects and costs of CP. Funded by: Heart Foundation - Scholarship-Health Professional ($90,000); University of Tasmania.
  • GRANT
    Coronary Artery calcium score: Use to Guide management of Hereditary Coronary Artery Disease (CAUGHT-CAD)
    1 Jan 2015 - 31 Dec 2020
    People funded by this grant:
    • Marwick T,
    • Nicholls S,
    • Watts G,
    • Worthley S,
    • Tonkin A
    Project Total: $2,802,386; Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Project ($5,604,772); University of Tasmania.
  • GRANT
    Detection and management of subclinical pulmonary vascular disease
    1 Jan 2015 - 31 Dec 2015
    People funded by this grant:
    • Marwick T,
    • Wright L,
    • Sharman J
    Project Total: $110,000; Pulmonary hypertension is a debilitation condition, with a 3 year survival rate of only 50%. Tasmania currently has a higher prevalance and incidence of pulmonary hypertension related to connective tissue disease than other regions in Australian. There is a large disease registry that for over 10 years has been aggressively screening and treating patients at only mild onset of this condition. This involves treating patients with vasodilator therapies. This is believed to improve exercise capacity, mobility, vascular spasm, right heart function and overall quality of life. It is not yet clear if the strategy of early treatment improves hard clinical outcomes and whether this is cost effective. This is important as the cost of maintaining these patients on treatments over a long term period need to be justified. We aim to look at a wide range of aspects of this disease process. Initial, at the microvascular level to determine how this affects functional decline in patients, to the function of the right ventricle and how new research methods are able to detect changes earlier. We will also asses whether timing of intervention impacts upon health status, and what the cost efficiency of early intervention regarding disease outcomes and quality of life. Funded by: Heart Foundation - Scholarship-Health Professional ($110,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Evidence Appraisal to inform guidelines for the management of Acute Coronary Syndrome
    1 Jan 2015 - 31 Dec 2015
    People funded by this grant:
    • Winzenberg T,
    • McKercher C,
    • Makin J,
    • Marwick T
    Project Total: $63,000; Heart Foundation requires an update to its Guidelines for the Management of Acute Coronary Syndromes. A technical Expert Working Group has been established to oversee the development of the guideline, with writing groups covering the topics of Chest Pain, Non-STEACS, STEMI, and Secondary Prevention, together with a consultative Reference group. The scope of the guideline will cover pre-hospital care through to discharge: assessing risk stratification, diagnostic/testing, routine Invasive and non-invasive procedures, medical management and secondary prevention. Evidence appraisal is a key phase to inform updates to the guideline and the summary of assessed literature will be used by the Expert Working Group as the basis to formulate recommendations. Development of the guideline, including evidence appraisal, Is aligned to NHMRC standards for Australian guideline development. Funded by: KP Health ($63,000); University of Tasmania.